Experimental cancer combo trial halted early
NCT ID NCT05147350
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called RP-6306 combined with standard chemotherapy (FOLFIRI) in 38 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. However, the study was terminated early, so no final results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RP-6306 (a PKMYT1 inhibitor) combined with FOLFIRI chemotherapy
What this could lead to
If successful, this could point toward a new combination treatment for advanced solid tumors that have stopped responding to standard therapy.
What could go wrong
This was a very early (Phase 1) trial that was terminated, so no conclusions can be drawn. The combination may cause significant side effects, and it is unclear if it will work in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
# 2001, Princess Margaret Cancer Centre
Toronto, Ontario, ON M5G 2M9, Canada
-
# 3003, Sarah Cannon Research Institute
London, W1G 6AD, United Kingdom
-
# 5002, South Texas Accelerated Research Therapeutics
Madrid, Spain
-
# 5003, Hospital Universitario HM Sanchinarro
Madrid, Spain
-
#1001, The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
#1008, Columbia University
New York, New York, 10032, United States
-
#1013, The University of Utah, Huntsman Cancer Center
Salt Lake City, Utah, 84112, United States
-
#1019, UCLA, Westwood Cancer Center
Los Angeles, California, 90095, United States
-
#1022, Moffitt Cancer Center
Tampa, Florida, 33612, United States